- Trial phase
- Approved/Marketed
- Time to market
- Already launched and marketed in Europe (Spain, Portugal, Austria) since 2023-2024.
- Why 3/10
- AdTab is an already-approved, marketed product (launched in Spain and Portugal in 2023, available in Austria by 2024) with no pending regulatory decision or pivotal readout scheduled in the next ~12 months. It is a small regional brand within Elanco's much larger Credelio lotilaner franchise, so no hard dated binary catalyst exists.
AdTab is a minor regional brand extension of Elanco's lotilaner (Credelio) franchise, launched in select European markets. It faces heavy competition from established flea/tick brands (Bravecto, NexGard, Simparica) and Elanco's own Credelio line. No upcoming binary catalysts exist for this specific product; watch Elanco's broader pet health portfolio (Credelio Quattro, Zenrelia) for material drivers.
Price Chart
Executive Summary
AdTab is Elanco's brand name for lotilaner flea and tick chewable tablets sold in select European markets (Spain, Portugal, Austria). It contains the same active ingredient as Elanco's larger US Credelio franchise. Launched in Spain and Portugal in July 2023, AdTab is a commercially available, approved product with no pending regulatory catalysts. It is a very small part of Elanco's diversified animal health business, which generated $1.265 billion in Q3 2026 revenue. The stock trades at around $25.80 with a consensus analyst price target of $30.69 (19% implied upside) and 19 of 22 analysts rating it Buy or Strong Buy.
How It Works
AdTab is a chewable tablet for dogs and cats that kills fleas and ticks. Its active ingredient, lotilaner, targets the nervous system of insects and arachnids (but not mammals), causing rapid paralysis and death of the parasites. It is given monthly with food.
Trial Status
AdTab is a commercially available product, not in clinical trials. It contains lotilaner, the same active ingredient as Elanco's Credelio line, which has FDA approval in the US and regulatory approvals in Europe.
The Two-Sided Case
Upcoming Catalysts
- No upcoming catalysts specific to AdTab. For Elanco broadly, watch Q4 2026 earnings and continued adoption of Credelio Quattro and Zenrelia.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Elanco Animal Health Inc 8-K ELAN ·Originating report